Standard Contracts
Exhibit 4.23 CONTROL DELIVERY SYSTEMS, INC. SEVERANCE AGREEMENT AGREEMENT made this 20th day of February, 2004, by and between Paul Ashton ("Executive") and Control Delivery Systems, Inc. (the "Company"). Whereas, the Board of Directors of the Company...Severance Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 2nd, 2012 • pSivida Corp. • Laboratory analytical instruments • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 1, 2012, between pSivida Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Exhibit 4.26 FIRST AMENDMENT CONTROL DELIVERY SYSTEMS, INC. SEVERANCE AGREEMENT This First Amendment to Severance Agreement (this "Amendment") made this 17th day of August, 2004 (the "Amendment Effective Date"), by and between Paul Ashton...Severance Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments
INDEMNIFICATION AGREEMENTIndemnification Agreement • March 8th, 2024 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments
This Indemnification Agreement (“Agreement”) is made as of - by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and - (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
BETWEENLicense Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments • New York
Controlled Equity OfferingSM Sales AgreementSales Agreement • August 5th, 2020 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Exhibit 4.3 THIS WARRANT AND ANY SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN...Warrant Agreement • March 28th, 2006 • pSivida LTD • Laboratory analytical instruments • New York
AGREEMENT BETWEENManufacturing Agreement • January 20th, 2005 • pSivida LTD
Exhibit 4.6 FORM OF REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments • New York
Exhibit 4.2 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement, dated as of the date of acceptance set forth below, is between PSIVIDA LIMITED, an Australian company (the "Company"), and the undersigned (the "Buyer"). The Company...Securities Purchase Agreement • March 28th, 2006 • pSivida LTD • Laboratory analytical instruments
EYEPOINT PHARMACEUTICALS, INC. 12,727,273 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 31st, 2024 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments
EYEPOINT PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • January 18th, 2019 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
CONFIDENTIAL pSivida Corp.Placement Agent Agreement • August 2nd, 2012 • pSivida Corp. • Laboratory analytical instruments • New York
14,402,000 American Depositary Shares and Warrants to Purchase 5,760,800 American Depositary Shares Each American Depositary Share Representing Ten Ordinary Shares PSIVIDA LIMITED PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • July 2nd, 2007 • pSivida LTD • Laboratory analytical instruments • New York
PSIVIDA CORP. 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 8th, 2016 • pSivida Corp. • Laboratory analytical instruments • New York
pSivida Corp., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), (i) 4,000,000 shares (the “ Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) the grant by the Company to the Underwriters of the option described in Section 1 hereto to purchase, severally and not jointly, all or any part of 440,000 shares of Common Stock (the “Option Shares,” and together with the Firm Shares, the “Shares”) . The respective amounts of the Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.
INDENTURE DATED AS OF , 20 BETWEEN EYEPOINT PHARMACEUTICALS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in SeriesIndenture • October 20th, 2023 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
THIS INDENTURE, dated as of , 20 , between EYEPOINT PHARMACEUTICALS, INC., a corporation duly organized and existing under the laws of the State of Delaware (herein called the “Company”), and , as trustee (herein called the “Trustee”).
Form of Registration Rights AgreementRegistration Rights Agreement • November 15th, 2005 • pSivida LTD • Laboratory analytical instruments • New York
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of November 15, 2005, by and among pSivida Limited, an Australian corporation, with headquarters located at Level 12 BGC Centre, 28 The Esplanade, Perth Australia 6000 (the "Company"), and the undersigned buyers (each, a "Buyer" and collectively, the "Buyers").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 26th, 2006 • pSivida LTD • Laboratory analytical instruments • New York
SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of September 18, 2006 by and among pSivida Limited, an Australian corporation, with headquarters located at Level 12, BGC Centre, 28 The Esplanade, Perth, WA 6000 Australia (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers").
ANDCollaboration Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments • Georgia
PSIVIDA CORP. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • February 8th, 2017 • pSivida Corp. • Laboratory analytical instruments • New York
pSivida Corp., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), as follows:
Exhibit 4.22 AMENDED AND RESTATED CONTROL DELIVERY SYSTEMS, INC. CHANGE OF CONTROL AGREEMENT AGREEMENT made this 17th day of August, 2004, by and between Lori Freedman ("Executive") and Control Delivery Systems, Inc. (the "Company"). Whereas, the...Change of Control Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments
INDENTURE DATED AS OF , 20 BETWEEN EYEPOINT PHARMACEUTICALS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in SeriesIndenture • August 8th, 2024 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
THIS INDENTURE, dated as of , 20 , between EYEPOINT PHARMACEUTICALS, INC., a corporation duly organized and existing under the laws of the State of Delaware (herein called the “Company”), and , as trustee (herein called the “Trustee”).
Securities Purchase Agreement, dated October 5, 2005, between pSivida Limited and the investor listed on the Schedule of Buyers attached theretoSecurities Purchase Agreement • November 15th, 2005 • pSivida LTD • Laboratory analytical instruments • New York
SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of October 5th 2005 by and among pSivida Limited, an Australian corporation, with headquarters located at Level 12, BGC Centre, 28 The Esplanade, Perth, WA 6000 Australia (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers").
EMPLOYMENT AGREEMENTEmployment Agreement • May 9th, 2024 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • Massachusetts
This Employment Agreement (hereinafter the “Agreement”) is made as of March 1, 2024 (the “Effective Date”), by and between Ramiro Ribeiro, M.D., Ph.D, who currently resides at *** (“Employee”) and EyePoint Pharmaceuticals, Inc. (hereinafter together with its subsidiaries, and related or affiliated entities referred to as the “Company”), having its headquarters at 480 Pleasant Street, Suite C-400, Watertown, Massachusetts 02472 (collectively the “Parties”).
GUARANTYGuaranty • September 15th, 2006 • pSivida LTD • Laboratory analytical instruments • New York
GUARANTY, dated as of September 14, 2006 made by each of the undersigned (each a "Guarantor", and collectively, the "Guarantors"), in favor of CASTLERIGG MASTER INVESTMENTS LTD., a company organized under the laws of the British Virgin Islands, in its capacity as collateral agent (in such capacity, the "Collateral Agent") for the "Buyers" (as defined below) party to the Securities Purchase Agreement, dated as of October 5, 2005 as amended by the First Amendment dated the date hereof (as further amended, restated or otherwise modified from time to time, the "Securities Purchase Agreement").
ContractRegistration Rights Agreement • June 27th, 2018 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
This SECOND REGISTRATION RIGHTS AGREEMENT (as it may be amended from time to time in accordance with the terms hereof, the “Agreement”), dated as of June 25, 2018, is made by and among EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and EW Healthcare Partners L.P., EW Healthcare Partners-A L.P. and each other Person identified on the signature pages hereto as an “Investor” (together with their Permitted Transferees that become party hereto, the “Investors”).
WITNESSETH:Commercial Sublease • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments
CREDIT AGREEMENT amongCredit Agreement • March 29th, 2018 • pSivida Corp. • Laboratory analytical instruments
This CREDIT AGREEMENT (as may be amended, restated, supplemented, or otherwise modified from time to time, this “Agreement”) dated as of March 28, 2018 (the “Closing Date”), among PSIVIDA CORP., a Delaware corporation (“Borrower”), the financial institutions party hereto from time to time as lenders (each a “Lender” and collectively, the “Lenders”) and SWK FUNDING LLC (in its individual capacity, “SWK”), as Agent for all Lenders.
SECOND SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 29th, 2018 • pSivida Corp. • Laboratory analytical instruments • New York
This Second Securities Purchase Agreement (this “Agreement”) is dated as of March 28, 2018, by and among pSivida Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT INDUCEMENT AWARDPerformance-Based Restricted Stock Unit Award Agreement • December 23rd, 2016 • pSivida Corp. • Laboratory analytical instruments • Delaware
Pursuant to this agreement, as amended and restated on December 21, 2016, (this “Agreement”), pSivida Corp., a Delaware corporation (the “Company”), hereby grants an award (the “Award”) of performance-based restricted stock units (the “Restricted Stock Units”) to the Grantee named above. The Award is granted to the Grantee in connection with her entering into Employment with the Company and is regarded by the parties as an inducement material to the Grantee’s entering into Employment within the meaning of NASDAQ Listing Rule 5635(c).
PSIVIDA CORP. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • December 20th, 2013 • pSivida Corp. • Laboratory analytical instruments • New York
Exhibit 4.31 CONTROL DELIVERY SYSTEMS, INC. 2001 INCENTIVE PLAN Restricted Stock Award Agreement The undersigned employee ("Employee") has been granted an award (the "Award") of restricted stock from Control Delivery Systems, Inc. (the "Company")...Restricted Stock Award Agreement • January 18th, 2006 • pSivida LTD • Laboratory analytical instruments • Delaware
UNDERWRITING AGREEMENT February 21, 2020Underwriting Agreement • February 24th, 2020 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
EyePoint Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 15,000,000 shares of its common stock (the “Firm Shares”), par value $0.001 per share (the “Common Stock”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,250,000 shares of Common Stock (the “Additional Shares”) as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”). To the extent there are no additional underwriters listed on Schedule I, the term “Represen
DATED 5 December 2006 SERVICE AGREEMENT STEPHENSON HARWOOD One, St. Paul's Churchyard London EC4M 8SH Tel: 020 7329 4422 Fax: 020 7606 0822 Ref: 1040Service Agreement • December 8th, 2006 • pSivida LTD • Laboratory analytical instruments
EMPLOYMENT AGREEMENTEmployment Agreement • November 19th, 2019 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • Massachusetts
This Employment Agreement (hereinafter the “Agreement”) is made as of November 14, 2019, by and between George O. Elston, who currently resides at xxx (“Employee”) and EyePoint Pharmaceuticals, Inc. (formerly pSivida, Inc. and hereinafter together with its parent, subsidiary, and related or affiliated entities referred to as the “Company”), having its headquarters at 480 Pleasant Street, Suite B300, Watertown, Massachusetts 02472 (collectively the “Parties”).
